drugset / Trial / NCT03113253

TRANexamic Acid to Reduce Bleeding in BURN Surgery

NCT03113253 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Excision and grafting in burn patients can lead to severe blood loss. A preliminary study conducted in Saint Joseph Saint Luc Hospital showed that the total median blood loss was 1412 mL (1). Transfused patients had a total median blood loss of 2468 mL and an average number of 4 packed red blood cells (PRBC) administered. Among the various methods that help limit blood loss, tranexamic acid, which has been proved useful in traumatology and surgery, has not been sufficiently studied in burn patients. A preliminary study in 27 burned patients showed a reduction of blood loss with tranexamic acid (2). Objective of TRANBURN study is to demonstrate that tranexamic acid help limit blood loss and reduces the use of blood products.

Timeline

Start
2016-09-22
Primary completion
2021-11-02
Completion
2021-11-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g Intravenous

Indications

No indication recorded.